TJ C4GM
Alternative Names: TJ-C4GMLatest Information Update: 28 Mar 2024
Price :
$50 *
At a glance
- Originator I-MAB Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral)
- 21 Feb 2020 TJ C4GM is available for licensing as of 21 Feb 2020. http://www.i-mabbiopharma.com/
- 21 Feb 2020 Preclinical trials in Solid tumours in China (Parenteral) (I-MAB Biopharma pipeline, February 2020)